Advanced Magnetics passed an important milestone earlier thismonth when the Food and Drug Administration issued a letter statingthat the new drug application for the company's Feridex MRI contrastagent is approvable. Advanced Magnetics, of Cambridge, MA,
Advanced Magnetics passed an important milestone earlier thismonth when the Food and Drug Administration issued a letter statingthat the new drug application for the company's Feridex MRI contrastagent is approvable. Advanced Magnetics, of Cambridge, MA, saidthat it is working with the FDA on final labeling for the agentas well as to resolve several questions relating to the NDA, whichwas filed in February 1994.
Feridex is an intravenous contrast agent designed to enhanceprimary and metastatic tumors in the liver on MRI scans. AdvancedMagnetics has licensed the agent to Berlex Laboratories in theU.S. and Canada (SCAN 2/15/95). Feridex is sold in Europe by Guerbetunder the trade name Endorem.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.